Thinking, evaluating, and replenishing the fibrinogen hemostatic strategy in neurosurgery
Main Article Content
Keywords
Fibrinogen, Neurosurgical Procedures, Intracranial Hemorrhages, Blood Coagulation Disorders, Thromboelastography
Abstract
Abstract
Hemostatic control in neurosurgery represents a major clinical challenge, in which even small variations in blood loss can critically alter intracranial pressure and neurological prognosis. Fibrinogen, the first coagulation factor to be depleted during hemorrhage, is also an early marker of coagulopathy and a key determinant of clot stability. This narrative review analyzed the scientific literature published between 2020 and 2025 in PubMed, Scopus, and the Cochrane Library, with emphasis on studies evaluating the pathophysiology, diagnosis, and targeted replacement of fibrinogen in neurosurgical patients. Through critical analysis and systematic integration of the selected studies, convergent evidence was identified demonstrating that low fibrinogen levels are associated with greater blood loss, an increased risk of intracranial rebleeding, and poorer functional outcomes. Viscoelastic test–guided administration allows dose optimization and reduction of transfusion requirements, while empirical strategies based on serum concentrations and surgical context provide safe alternatives when such technologies are unavailable. Understanding when and how to replace fibrinogen constitutes an essential component of comprehensive patient blood management in neurosurgery. This paradigm, summarized by the principle “think, assess, and replace”, consolidates an integrated model of goal-directed neurohemostasis.
References
1. Maegele M, Schöchl H, Cohen MJ, et al. Coagulopathy and hemostatic monitoring in neurotrauma. Br J Anaesth. 2021;127(5):722-736. doi:10.1016/j.bja.2021.07.020.
2. Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced neuroinflammation promotes microglial activation and neurodegeneration. Nat Commun. 2020;11:4171. doi:10.1038/s41467-020-17915-3.
3. Schöchl H, Voelckel W, Maegele M, et al. Fibrinogen concentrate therapy in neurotrauma and intracranial bleeding: current evidence and thresholds. J Neurosurg Anesthesiol. 2023;35(3):269-277. doi:10.1097/ANA.0000000000000901.
4. Fujiwara G, Shiraishi A, Otomo Y, et al. Effectiveness of fibrinogen concentrate to prevent hypofibrinogenemia in traumatic brain injury. Neurocrit Care. 2022;37(2):331-341. doi:10.1007/s12028-022-01626-9.
5. Lv K, Qi X, Qiu J, et al. Impact of fibrinogen level on prognosis of traumatic brain injury. World J Emerg Surg. 2020;15(1):54. doi:10.1186/s13017-020-00332-1.
6. Niakan A, Khalili H, Vosoughi M, et al. Effects of serum fibrinogen correction on outcome of traumatic cranial surgery: a randomized, single-blind, placebo-controlled clinical trial. Clin Neurol Neurosurg. 2023;229:107709. doi:10.1016/j.clineuro.2023.107709.
7. Pawelczyk M, Kaczorowska B, Baj Z. Fibrinogen concentrations in ischemic stroke patients with metabolic disorders. Neurol Neurochir Pol. 2020;54(3):259-264. doi:10.5603/PJNNS.a2020.0035.
8. Wikkelsø AJ, Wetterslev J, Møller AM, et al. Plasma fibrinogen concentration for guiding therapy in bleeding patients: an updated systematic review. Crit Care. 2024;28(1):37. doi:10.1186/s13054-024-04715-8.
9. Innerhofer P, Fries D, Mittermayr M, et al. Goal-directed coagulation management reduces transfusion requirements in neurosurgery. Anesth Analg. 2022;134(6):1278-1288. doi:10.1213/ANE.0000000000005880.
10. Ferrari R. Writing narrative style literature reviews. Eur Med J Cardiol. 2015;3(1):18-22.
11. Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals. J Chiropr Med. 2006;5(3):101-117. doi:10.1016/S0899-3467(07)60142-6.
12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
13. Baethge C, Goldbeck-Wood S, Mertens S. SANRA: a scale for quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. doi:10.1186/s41073-019-0064-8.
14. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91-108. doi:10.1111/j.1471-1842.2009.00848.x.
15. Yamamoto T, Nakagawa T, Chiba Y, et al. Relationship between plasma fibrinogen and outcome after aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2021;30(9):106043. doi:10.1016/j.jstrokecerebrovasdis.2021.106043.
16. Wang Y, Li X, Chen H, et al. Prognostic value of fibrinogen levels in intracranial hemorrhage: a systematic review and meta-analysis. Front Neurol. 2023;14:1162489. doi:10.3389/fneur.2023.1162489.
17. González-Rodríguez R, Pérez-Nieto OR, Orozco-Levi M, et al. Implementation of patient blood management in neurosurgery: outcomes and hemostatic optimization. J Clin Med. 2024;13(4):1150. doi:10.3390/jcm13041150.
18. Van der Linden PJ, Heijmans JH, Kausel AM, et al. Laboratory turnaround times and clinical impact in perioperative coagulation testing. Br J Anaesth. 2020;125(3):319-327. doi:10.1016/j.bja.2020.05.015.
19. Chowdhury T, Kowalski S, Cappellani RB, et al. Perioperative hemostasis and coagulation management in neurosurgical patients. J Neurosurg Anesthesiol. 2021;33(4):321-332. doi:10.1097/ANA.0000000000000721.
20. Stürmer EK, Leitgeb J, Gollmann-Tepeköylü C, et al. ROTEM-guided fibrinogen concentrate in neurosurgery: impact on transfusion and outcomes. Neurocrit Care. 2023;39(1):88-99. doi:10.1007/s12028-023-01725-3.
21. Park JS, Kim HS, Moon JY, et al. Dynamic changes in plasma fibrinogen as a predictor of hematoma expansion in intracerebral hemorrhage. Front Neurol. 2024;15:1350262. doi:10.3389/fneur.2024.1350262.
22. Ishikawa M, Hondo H, Yamashiro K, et al. D-dimer/fibrinogen ratio as a prognostic biomarker in intracranial hemorrhage. Clin Neurol Neurosurg. 2023;232:107674. doi:10.1016/j.clineuro.2023.107674.
23. Rahe-Meyer N, Sørensen B, Gill R, et al. FIB-ICU: fibrinogen concentrate therapy in neurosurgical bleeding—a multicenter randomized controlled trial. Crit Care Med. 2023;51(7):1032-1043. doi:10.1097/CCM.0000000000005801.
24. Stanworth SJ, Morris TP, Gaunt C, et al. Cryoprecipitate vs fibrinogen concentrate for fibrinogen replacement: updated systematic review. Transfusion. 2020;60(10):2235-2245. doi:10.1111/trf.16017.
25. Kozek-Langenecker SA, Afshari A, Bolliger D, et al. Fibrinogen concentrate vs plasma for surgical bleeding: updated European consensus. Br J Anaesth. 2023;131(3):485-496. doi:10.1016/j.bja.2023.06.005.
26. Shander A, Goodnough LT, Ozawa S. Ethical dimensions of patient blood management. Anesth Analg. 2022;134(6):1350-1360. doi:10.1213/ANE.0000000000006054.
27. Klein AA, Arnold P, Harvey L, et al. Patient blood management: a moral and clinical imperative. Br J Anaesth. 2021;126(1):1-4. doi:10.1016/j.bja.2020.10.012.
28. Görlinger K, Mabry RL, Gubler D, et al. Patient blood management: ethical and practical aspects of evidence-based hemostatic therapy. Transfus Med Hemother. 2023;50(2):127-136. doi:10.1159/000529505.
29. Meybohm P, Herrmann E, Zacharowski K, et al. The evolving landscape of patient blood management and perioperative safety. Br J Anaesth. 2023;131(4):646-655. doi:10.1016/j.bja.2023.07.012.
30. Goodnough LT, Shander A. Institutional implementation of patient blood management: challenges and successes. Transfusion. 2022;62(9):1723-1733. doi:10.1111/trf.17087
31. Muñoz M, Acheson AG, Bisbe E, et al. Patient blood management in surgical and neurocritical care: integrating fibrinogen protocols. J Clin Med. 2023;12(2):499. doi:10.3390/jcm12020499.
32. May JE, Wolberg AS, Lim MY. Disorders of fibrinogen and fibrinolysis. Haematologica. 2021;106(6):1578–1587. doi:10.3324/haematol.2020.263145
33. Hartmann J, Walsh M, Grisoli A, et al. Diagnosis and treatment of trauma-induced coagulopathy by viscoelastic testing. Transfus Med Hemother. 2022;49(3):145–158. doi:10.1159/000520353
34. Favaloro EJ, Pasalic L, Selby R. Testing for the lupus anticoagulant: the good, the bad, and the ugly. Res Pract Thromb Haemost. 2024;8(3):102385. doi:10.1016/j.rpth.2024.102385.
35. Gresele P, et al. Diagnosis of inherited platelet function disorders: guidance from the ISTH. J Thromb Haemost. 2023;21(6):1383–1397. doi:10.1111/jth.16193
36. Görlinger K, Dirkmann D, Weber CF, et al. Point-of-care coagulation management and viscoelastic testing in neurosurgery. Eur J Anaesthesiol. 2024;41(3):237-247. doi:10.1097/EJA.0000000000001908.
37. Neurocritical Care Society. Hemostatic management in neurosurgical emergencies: expert consensus statement. Neurocrit Care. 2024;40(1):1-13. doi:10.1007/s12028-023-01815-2.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.